Orr Shormoni, Inga Zerr, Katrin Thüne, Eirini Kanata, Juan Carlos Espinosa, Franc Llorens, Matthias Schmitz, Olivier Andreoletti, Athanasios Dimitriadis, Vincenzo Capece, Nikolaos Bekas, Stefan Bonn, Dimitra Dafou, Alba Marín-Moreno, Juan María Torres, Isidre Ferrer, Konstantinos Xanthopoulos, Theodoros Sklaviadis, Aristotle University of Thessaloniki, Neurodegenerative Diseases Research Group, Department of Pharmacy, School of Health Sciences, Aristotle University of Thessaloniki-Aristotle University of Thessaloniki-School of Health Sciences, Aristotle University of Thessaloniki-Aristotle University of Thessaloniki, Institute of Health Carlos III, Network Center for Biomedical Research of Neurodegenerative Diseases, University Medical Center Göttingen (UMG), Department of Genetics, Development and Molecular Biology, School of Biology, Faculty of Sciences, German Research Center for Neurodegenerative Diseases - Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Laboratory of Pharmacology, Department of Pharmaceutical Sciences, School of Health Sciences, Centro de Investigacion en Sanidad Animal (INIA-CISA), Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria = National Institute for Agricultural and Food Research and Technology (INIA), Institute Developmental Biochemistry, Microarray and Deep-Sequencing Core Facility, University Medical Center Göttingen (UMG)-University Medical Center Göttingen (UMG), Interactions hôtes-agents pathogènes [Toulouse] (IHAP), Institut National de la Recherche Agronomique (INRA)-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Department of Pathology and Experimental Therapeutics, Universitat de Barcelona (UB), This study was supported by the Research Funding program ARISTEIA II (Grant RNA edit 3739), cofinanced by the European Union (European Social Fund-ESF) and Greek national funds through the Operational Program 'Education and Lifelong Learning' of the National Strategic Reference Framework (to T.S.), the Alliance BioSecure Foundation project 'RNA editing in CJD' (T.S. and I.Z.), Federal Ministry of Education and Research grants within the German Network for Degenerative Dementia (to I.Z.), the Red Nacional de Priones AGL2015-71764-REDT-MINECO (to F.L., I.Z., J.M.T., and I.F.), the Spanish Ministry of Health-Instituto Carlos III/Fondo Social Europeo CP16/00041 (to F.L.), by the IKYDA Greek-German collaboration Project 57260006 (to F.L., I.Z., D.D., and T.S.), and and in part by Grant AGL2016-78054-R (AEI/FEDER, UE).
Significance Prion diseases are fatal neurodegenerative disorders characterized by rapidly progressive dementia. Sporadic Creutzfeldt–Jakob disease (sCJD) is the most prevalent. We report that, specific gene-expression alterations utilizing a reliable in vivo mouse model (tg340-PRNP129MM) with sCJD MM1 subtype, correlate with human disease manifestations in the brain cortex related to disease progression. RNA-editing functions mediated by the APOBEC and ADAR deaminases possibly affecting protein expression necessary for normal brain function, are altered in disease stages. Our data provide powerful evidence, derived from a humanized sCJD mouse model and human autopsy material, discerning the critical role of gene expression and RNA-editing signatures, introducing disease-associated targets that can be extrapolated in other neurodegenerative disorders with common clinical and molecular features., Prion diseases are fatal neurodegenerative disorders caused by misfolding of the normal prion protein into an infectious cellular pathogen. Clinically characterized by rapidly progressive dementia and accounting for 85% of human prion disease cases, sporadic Creutzfeldt–Jakob disease (sCJD) is the prevalent human prion disease. Although sCJD neuropathological hallmarks are well-known, associated molecular alterations are elusive due to rapid progression and absence of preclinical stages. To investigate transcriptome alterations during disease progression, we utilized tg340-PRNP129MM mice infected with postmortem material from sCJD patients of the most susceptible genotype (MM1 subtype), a sCJD model that faithfully recapitulates the molecular and pathological alterations of the human disease. Here we report that transcriptomic analyses from brain cortex in the context of disease progression, reveal epitranscriptomic alterations (specifically altered RNA edited pathway profiles, eg., ER stress, lysosome) that are characteristic and possibly protective mainly for preclinical and clinical disease stages. Our results implicate regulatory epitranscriptomic mechanisms in prion disease neuropathogenesis, whereby RNA-editing targets in a humanized sCJD mouse model were confirmed in pathological human autopsy material.